FRUCTOSE


Synonyms	D-fructose Dietade dietary foods Fructose Levulose NSC-760385 NSC-9250 Nevulose Sugar fruit fine Topiramate impurity, fructose-
Status
Molecule Category	Free-form
ATC	V06DC02
UNII	B986VTP17J
EPA CompTox	DTXSID5023081


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	RFSUNEUAIZKAJO-ARQDHWQXSA-N
Smiles	OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O
InChI	InChI=1S/C6H12O6/c7-1-3-4(9)5(10)6(11,2-8)12-3/h3-5,7-11H,1-2H2/t3-,4-,5+,6-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C6H12O6
Molecular Weight	180.16
AlogP	-3.22
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	5.0
Number of Rotational Bond	2.0
Polar Surface Area	110.38
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	12.0

Assay Description	Organism	Bioactivity
Compound was tested for inhibition of Human acrosin by ketohexoses	None	66.0 %
Compound was tested for inhibition of Human acrosin by ketoses	None	47.0 %
Compound was tested for inhibition of Human acrosin by phosphorylated monosaccharides	None	46.0 %

Related Entries

Cross References

Resources	Reference
ChEBI	28645
ChEMBL	CHEMBL604608
FDA SRS	B986VTP17J
KEGG	C02336
PDB	FRU
PubChem	5984
SureChEMBL	SCHEMBL3966
ZINC	ZINC000001529270

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).